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Prostate cancer affects a significant proportion of men worldwide. Evidence from genetic and clinical studies suggests that there
may be a causal association between prostate cancer and the human papilloma virus (HPV). As HPV is a vaccine-preventable
pathogen, the possibility of a role in prostate cancer causation may reinforce the importance of effective HPV vaccination
campaigns. This is of particular relevance in light of the COVID-19 pandemic, which may have considerable effects on HPV vaccine
uptake and distribution.
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Prostate cancer is the commonest solid-organ malignancy in
men worldwide and represents a significant healthcare burden.
Although the feasibility of modifying recognised risk factors for
prostate cancer is currently low, there is evidence to suggest
that the vaccine-preventable pathogen, Human Papilloma Virus
(HPV) may be associated with the pathogenesis of prostate
cancer [1]. HPV is most notably known for its ability to cause
cervical cancer in women, but it is also associated with
anogenital and oral cancers [2]. There are multiple subtypes of
HPV and these can be classified according whether they are high
or low-risk for the development of cancer [3]. Recent work has
identified the presence of high-risk HPV in prostate tumours and
has led to speculation that there may be a causal relationship
between HPV exposure and the development or promotion of
cancer in the prostate [2–6]. It is therefore important to explore,
or indeed question this possibility, especially given the
established efficacy of HPV vaccination and the negative effects
of the coronavirus disease 2019 (COVID-19) pandemic on HPV
vaccine delivery [7].
The potential role of HPV in the causation of prostate cancer has
been the subject of considerable debate and the focus of several
recent systematic reviews (Table 1). HPV is one of several
microorganisms found in the prostate gland, and has been
identified in both benign and cancerous samples [4]. Additionally,
studies suggest that the prevalence of high-risk HPV in benign
prostatic tumours is comparable to those found in the presence of
prostate cancer [3], and as such, it could be argued that the
presence of HPV may be coincidental. However, a recent
systematic review of 26 studies by Lawson and Glenn [4]
concluded that there was an increased proportion of high-risk
HPV types in prostate cancer compared to benign and healthy
tissue. This is supported by results from a recent meta-analysis
which suggested that HPV infection was associated with an
increased likelihood of prostate cancer development, with an
odds ratio of 2.27 (95% confidence interval, 1.40–3.69) [5]. The
apparent discrepancy in findings across studies may be attributed
to differing experimental techniques used to confirm the presence
of HPV infection. Moreover, the suitability of serology to identify
HPV has been questioned, as it may not provide a true assessment
of HPV infection within the prostate itself [4]. Also, there is a
variation in the prevalence and distribution of HPV subtypes
globally, and it is possible that this may have been a contributing
factor to the observed heterogeneity of findings in case–control
studies [4, 5]. Indeed, assessing a person’s degree of exposure to
HPV may not provide sufficient foundation to infer effect from this
pathogen within the prostate.
However, at the genetic level, there appears to be variation in
the nature of HPV infection between benign and cancerous
tumours. A study by Glenn et al. [3] demonstrated a reduction in
the expression of the E6 and E7 HPV oncogenes during the
progression of prostate tumours from benign to malignant states.
Using RNA sequencing, the same study found that HPV was likely
present in an activated state in a proportion of prostate cancers.
This evidence raises the possibility that HPV could be an early
pathogenic contributor to prostate cancer development, but may
have a diminished role in later stages [4]. This is substantiated by
the observation that koilocytes are present within some prostate
tumours [8]. These cells are indicative of HPV infection and are
known to signify the early stages of oncogenesis in cervical cancer
[4]. Of note, the possible role of HPV in prostate cancer causation
may differ from its mechanism of action in cervical carcinogenesis
[4]. In a population of immunocompromised patients, there
was a greater incidence in a variety of cancers, including cervical
malignancies, but the risk of prostate cancer was not increased [9].
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While some maintain that this evidence reduces the likelihood of a
role for HPV in prostate cancer causation, it may be argued instead
that these findings highlight the possibility of an indirect
mechanism of oncogenesis [4, 9]. HPV may lead to mutations in
APOBEC3B, a gene which has been found to have a protective role
against the effects of viruses [10]. Mutant versions of this gene
have been observed in prostatic tumours [11]. In addition, HPV
may play a role in apoptotic, inflammatory and angiogenic
processes within prostatic tissue, all of which are key elements of
carcinogenesis [1].
Due to the possible role of HPV in prostate cancer causation, it
may be argued that it is increasingly important to intensify
current HPV vaccination strategies, with a sustained gender-
neutral approach. This may be of greater relevance than ever
before, as the COVID-19 pandemic has posed a significant
challenge to HPV vaccination campaigns. Unfortunately, short-
term measures to mitigate the spread of COVID-19, such as
school closures and limited clinic visits, have led to a fall in HPV
vaccination rates [12]. In the United States, there was an 80%
reduction in HPV vaccine orders by the end of March 2020,
compared to the same time in the previous year [13, 14] and a
parallel marked reduction of HPV vaccine uptake in Europe [7]. It
is unclear what the long-term effects of this situation will be, but
there has been speculation that the increased vaccine hesitancy
seen during the COVID-19 pandemic could negatively impact
future HPV vaccination campaigns [14]. However, some maintain
that the successful results of COVID-19 vaccination efforts
could increase public confidence in vaccines, leading to greater
uptake of the HPV vaccine [7, 14]. Nonetheless, there is a need
to support the expeditious revivification of HPV vaccination
campaigns, redesigning them where necessary, to suit the
current circumstances.
Despite the incongruity of evidence surrounding HPV exposure
and prostate cancer causation, extant evidence suggests an
association worthy of further investigation. The significance of a
confirmed role of HPV in the development of prostate cancer is
weighty, and would strengthen calls for current generic vaccination
programmes [7], ultimately, providing greater protection for men at
risk, for whom modifiable risk factors have, as yet, been elusive.
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Table 1. Recent systematic reviews and meta-analyses examining the association between prostate cancer and HPV.
Review author, Ref. No. included studies Key findings
Russo et al. [2] 30 The odds of developing prostate cancer were increased in men positive for HPV-16 (pooled OR=
1.37, p < 0.01), but not in HPV-18 positive men.
Lawson et al. [4] 26 High-risk HPVs were identified in 22.6% of prostate cancers, compared to 8.6% of benign or normal
prostate tissues (p= 0.001).
Yin et al. [5] 24 In HPV-positive men, the pooled OR for developing prostate cancer was 2.27 (95% CI= 1.40–3.69).
Moghoofei et al. [6] 24 There was a positive association between HPV and prostate cancer (OR= 1.281, p= 0.026) and a
higher incidence of HPV-16 in prostate tumours.
No. Number, HPV human papilloma virus, OR odds ratio, p probability, CI confidence interval.
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